Academia.eduAcademia.edu

Multimodal analgesia after laparoscopic cholecystectomy

2007, European Journal of Anaesthesiology

Results: Univariate analysis: probability to suffer from nausea was 7.5-12 times greater for patients of A group than those of B group and 16.4-20 times larger than those of C group (respectively at first-second hour) (p Ͻ 0.01). Multivariate analysis: probability to find nausea was 17.8-25.6 times larger in A group than C group (at first-second hour) and 18.5 times greater than B group at the second hour (p Ͻ 0.01). Vomiting did not show significantly results. Conclusions: Acupuncture plus ondansetron was the best treatment to prevent nausea. Ondansetron alone prevented nausea while acupuncture alone was not efficacy as antiemetic procedure.

122 Pharmacology Results: Univariate analysis: probability to suffer from nausea was 7.5–12 times greater for patients of A group than those of B group and 16.4–20 times larger than those of C group (respectively at first-second hour) (p  0.01). Multivariate analysis: probability to find nausea was 17.8–25.6 times larger in A group than C group (at first-second hour) and 18.5 times greater than B group at the second hour (p  0.01). Vomiting did not show significantly results. Conclusions: Acupuncture plus ondansetron was the best treatment to prevent nausea. Ondansetron alone prevented nausea while acupuncture alone was not efficacy as antiemetic procedure. Reference: 1 K. Streitberger, M. Diefenbacher, A. Bauer et al Anaesthesia 2004; 59: 142–149. 9AP6-7 Propofol anesthesia modifies corticosterone secretion differently according to the circadian time G. Dispersyn, L. Pain, Y. Touitou Inserm U 713 Laboratoire de Biochimie Médicale et Biologie Moléculaire, Faculté de Médecine Pitié-Salpêtrière, Paris, France Background and Goal of Study: Because of potential chronobiotic properties of propofol (effect on biological clock) (1), we examined the effects in rats of a short duration propofol anaesthesia on corticosterone, the major glucocorticoid. Materials and Methods: Forty male Wistar rats were synchronized under a LD 12:12 cycle (12 h light, 12 h dark) during 4 weeks. One group was injected in the middle of the rest phase (CT6), another one was injected 2 hours before the beginning of the activity phase (CT10) and the third group was injected in the middle of the activity phase (CT16). On day 29, rats received either propofol injection (120 mg/kg) or intralipids and they were sacrificed by decapitation one hour after drug administration. Trunk blood was collected and centrifugated; serum was then separated and kept at  30°C until corticosterone assayed by using 125I RIA kits (MP Biomedicals, NY, USA). Results and Discussions: Propofol induced a significant increase in corticosterone secretion and disturbed its circadian rhythm. Propofol resulted in an increase of 108% (Student test, p  0.05), 61% (p  0.03) and 157% (p  0.006) of corticosterone in CT6, CT10 and CT16 groups respectively (see figure). 450 400 ng/ml Propofol 350 300 250 200 150 100 Intralipids 50 0 ct10 ct16 ct6 Conclusion(s): Propofol anaesthesia seems induce a desynchronization of corticosterone circadian rhythm by abolishing its morning peak and also increasing the total amount of corticosterone secretion, in rats. Reference: 1 Challet et al. Neuropsychopharmacology 2006. 9AP6-8 Multimodal analgesia after laparoscopic cholecystectomy I. Grecu, A.E. Nicolau, V. Merlan, M. Nicolau, I. Grintescu Anesthesiology and ICU, Clinical Emergency Hospital of Bucharest, Bucharest, Romania Background and Goal of Study: Multimodal analgesia is an important prerequisite for accelerated recovery after elective surgery. Our study goal was to investigate the effects of locally injected 0.25% ropivacaine (R) on postoperative pain after elective laparoscopic cholecystectomy. Materials and Methods: After Hospital Ethics Committee approval, 60 adult patients scheduled for laparoscopic cholecystectomy performed by the same surgeon were enrolled in a prospective, randomized, double-blind, placebocontrolled study over a period of 6 months (Jan–June 2006). All patients received the same general anesthesia protocol and 1 g iv paracetamol was infused after induction of anesthesia for postoperative analgesia, repeated each 6 hs postoperatively, up to 4 g/24 hs. Tramadol 50 mg iv bolus was used as rescue analgesic. After anesthesia induction, patients were randomized in 4 groups (n  15 pts, each): group A (20 ml preincisional saline infiltration at the abdominal wall and 20 ml R 0.25% intraperitoneal instillation), group B (20 ml R 0.25% preincisional infiltration and 20 ml saline intraperitoneal instillation), group C (A  B) and group P (placebo, both sites saline infiltration). Primary endpoints were VAS at movement at 0, 2, 6, 12 and 24 postoperative hs (0–10 cm), rescue analgesic requirements, PONV and length of hospital stay. Statistics: chi-square, one-way ANOVA (SPSS 13.0). Results and Discussions: We found no differences in demographics, length of surgery and of hospital stay (total: 3.38  0.22 days). VAS was significantly lower at all intervals in group C versus P and at 0, 6 and 12 hs in group C versus both groups A and B (p  0.05). Tramadol boluses required were significantly fewer in group C vs P (0.73  1.10 vs 1.93  1.03, p  0.017) and also the incidence of PONV (1 pt in group C vs 7 pts in group P, p  0.01). Conclusion(s): Ropivacaine 0.25% shows significant favorable effects on postoperative pain after laparoscopic cholecystectyomy only when using combined preincisional local infiltration and intraperitoneal instillation. Reference: 1 Louizos A.A et al. Surg Endosc 2005; 19: 1503–6. 9AP6-9 Safety of metoclopramide in PONV prophylaxis using doses higher than 10 mg intraoperatively J. Wallenborn, G. Gelbrich, M. Rudolph, D. Olthoff Department of Anaesthesiology and Intensive Care, University of Leipzig, Leipzig, Germany Background and Goal of Study: Doses of 25 and 50 mg metoclopramide (MCP) in combination with 8 mg dexamethasone (DEX) are effective in prophylaxis of postoperative nausea and/or vomiting (PONV; [1]). Safety and a fair trade-off of avoidance of PONV against adverse effects needs to be highlighted [2]. Materials and Methods: We reanalyzed the data of 3140 patients participating in a multi-centre study on PONV [1] and receiving randomized 0, 10, 25 or 50 mg MCP with special consideration of MCP-related immediate and delayed adverse events (AE). The case report forms contained fields of 18 expected AE and one free text item each for intraoperative and postoperative suspected AE. We performed a trend test using Kendall’s Tau (for event rate increasing with dose) and Fisher’s exact test (for increased event rate of any dose). Stepwise multiple regression analysis was used to identify predictors of AE. Results and Discussions: Only hypotension and tachycardia following study drug administration were clearly related to MCP and increasing dose. The incidence (95%-Confidence Interval) of either of these events were 8.8% (6.8–10.8), 11.2% (9.0–13.4), 12.9% (10.5–15.3), and 17.9% (15.2–20.6) for 0, 10, 25, and 50 mg MCP. These AE were more frequent in patients older than 50 years, but obesity seemed to be protective. MCP was also associated with movement disorders (MCP-MD): number needed to harm (NNH)  147 for any dose (78-) and 112 (60–1111) for 25 or 50 mg, impaired taste and smell: NNH  167 (93–5000), and hot flushes: NNH  182 (106–345). Duration of MCP-MD was predominantly  1 hour with subjective impairment of 4.7 (range 2–7). MCP-MD was associated with age  30 years. Gender, opioids, type of volatile anesthetic, and diabetes have no influence of MCP-MD. 3 definite and 3 suspected movement disorders occurred in the control group receiving only 8 mg DEX. Conclusion(s): Because of short-lasting and mostly self-limiting immediate AE and only occasionally occurring MCP-MD a single dose of 25 or 50 mg MCP given intraoperatively can be recommended even under aspects of safety. These results cannot be transferred to pediatric anesthesia or awake patients. References: 1 2 Wallenborn J, Gelbrich G, Bulst D et al. BMJ 2006; 333: 324–327. Carlisle JB, Stevenson CA. Cochrane 2006; CD004125. 9AP7-1 The efficacy of sugammadex in subjects with impaired renal function L. Staals, MMJ. Snoeck, E. Flockton, M. Heeringa, JJ. Driessen Anesthesiology, Radboud University Medical Center, Nijmegen, The Netherlands Background and Goal of Study: Sugammadex is a modified gammacyclodextrin that has been designed to encapsulate the neuromuscular